Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatologic changes associated with interleukin 2 administration.

A A Gaspari, M T Lotze, S A Rosenberg

    JAMA
    |September 25, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction to: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.

    Cell death and differentiation·2025
    Same author

    Correction: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.

    Oncogene·2025
    Same author

    Diagnostic dilemmas of Titanium Hypersensitivity in patients with medical implants: a case series.

    European annals of allergy and clinical immunology·2020
    Same author

    A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside.

    HNO·2020
    Same author

    Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Cross-elicitation responses to 2-methoxymethyl-p-phenylenediamine in p-phenylenediamine highly allergic volunteers using allergy alert test: the Italian experience.

    European annals of allergy and clinical immunology·2019
    Same journal

    WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

    JAMA·2026
    Same journal

    FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

    JAMA·2026
    Same journal

    HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

    JAMA·2026
    Same journal

    US Dietary Supplement Use Increasing, Especially in Older Adults.

    JAMA·2026
    Same journal

    Heat Stress From Climate Change Surges Globally.

    JAMA·2026
    Same journal

    Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

    JAMA·2026
    See all related articles

    Interleukin 2 (IL-2) immunotherapy can cause skin changes like redness and itching in cancer patients. These side effects, including rash and erythroderma, typically resolve after IL-2 treatment stops.

    Area of Science:

    • Oncology
    • Immunology
    • Dermatology

    Background:

    • Cancer immunotherapy utilizes agents like interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cells.
    • Understanding treatment-related side effects is crucial for patient management.

    Purpose of the Study:

    • To prospectively evaluate and characterize skin changes in cancer patients receiving IL-2 based immunotherapy.
    • To determine if cutaneous effects are mediated by IL-2 alone or in combination with LAK cells.

    Main Methods:

    • Prospective evaluation of ten cancer patients undergoing IL-2 and LAK cell immunotherapy.
    • Serial skin biopsies obtained at baseline, during IL-2 administration, and during IL-2/LAK cell infusion.
    • Clinical observation of skin eruptions, including onset, localization, and resolution patterns.

    Related Experiment Videos

    Main Results:

    • All patients developed a characteristic eruption of macular erythema, burning, and pruritus, typically on the head and neck.
    • The eruption began within 2-3 days of IL-2 infusion and resolved with desquamation 48-72 hours after cessation.
    • Histological examination showed non-specific changes, with a consistent finding of DR+/Leu-4+ lymphoid cells around dermal blood vessels.
    • No significant differences in clinical or histological features were observed between IL-2 alone and IL-2/LAK cell treatments.

    Conclusions:

    • Cutaneous side effects associated with IL-2 and LAK cell immunotherapy are primarily mediated by IL-2.
    • The observed skin eruption is a predictable, transient side effect of IL-2 treatment.